Article Text

other Versions

PDF
Correspondence
Expression of D-type cyclins in AL amyloidosis plasma cells
  1. John Cho Lee1,2,
  2. Hao Wu1,2,
  3. Tatiana B Prokaeva2,3,
  4. Carl O'Hara1,2,
  5. David C Seldin2,3
  1. 1Department of Pathology and Laboratory Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA
  2. 2Amyloid Treatment and Research Program, Boston University, Boston, Massachusetts, USA
  3. 3Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA
  4. Authors JCL and HW contributed equally to this paper.
  1. Correspondence to Dr. David C. Seldin, Amyloid Treatment and Research Program, 72 E. Concord Street, Boston, MA 02118 USA Fax: 617-638-4493 Tel: 617-638-4317; dseldin{at}bu.edu

Statistics from Altmetric.com

Introduction

Amyloid light chain (AL) amyloidosis is a plasma cell (PC) disorder characterised by the overproduction of monoclonal immunoglobulin light chains (LC). It can be treated effectively with chemotherapy with or without stem cell transplantation, proteasome inhibitors or immunomodulatory drugs.

Diagnosing AL amyloidosis requires the detection of tissue amyloid deposits in association with monoclonal immunoglobulin LC production, which can be detected by serum or urine immunofixation electrophoresis (S/UIFE), serum free light chain (FLC) assay and/or bone marrow assessment of clonal PCs.1 ,2 In some clinical circumstances, it may be necessary to prove the monoclonal LC nature of the amyloid using immunoelectron microscopy or mass spectrometry.3

The current modalities to demonstrate the clonality of amyloidogenic PCs in the bone marrow include flow cytometry, immunohistochemistry (IHC) and in situ hybridisation (ISH). Owing to the small volume of the PC population in AL amyloidosis, however, detection of clonal PCs is often difficult.4 ,5

Cyclin D dysregulation has been proposed to be a common mechanism in PC disorders, as in multiple myeloma; the majority of patients have dysregulated cyclin D expression.6 This has not been extensively investigated in AL amyloidosis. In this study, we evaluated cyclin D1, D2 and D3 protein expression in AL amyloidosis, and compared cyclin D positivity to other conventional laboratory parameters as a diagnostic tool and as a potential biomarker for minimal residual disease.

Methods

Patient selection

Thirty-four AL amyloidosis patients diagnosed based on published guidelines7 ,8 who had a bone marrow biopsy between June and August 2008 were included in this study, with permission of the Boston University Medical Center Institutional Review Board. Six patients were newly diagnosed, while 28 had received prior treatment including intravenous melphalan with autologous stem cell transplantation, oral …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.